Revive Therapeutics Explores the Use of Bucillamine for Long COVID

TORONTO, Feb. 01, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...

Kontrol Technologies Provides Corporate Update

TORONTO – Kontrol Technologies Corp. (Cboe CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”) provides a corporate update for January 2024. Completion of High-Temperature Dry Kiln Pilot and Initial Technology Sale Following the press release dated...

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

TORONTO, Jan. 24, 2024 – REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is arranging a private placement of a maximum of 85,714,285 units (each, a “Unit”), at a price of $0.035 per Unit, for gross proceeds of up to $3...

Kontrol Technologies Completes Sale of Operating Subsidiary

TORONTO – Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”), has completed the sale of its operating subsidiary ORTECH Consulting. The sale proceeds are $6.1 Million plus working capital of approximately $600,000, less...